The 2023-2028 World Outlook for Oncology Small Molecule Drug Discovery

The 2023-2028 World Outlook for Oncology Small Molecule Drug Discovery

This study covers the world outlook for oncology small molecule drug discovery across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

This study covers oncology small molecule drug discovery as defined by the North American Industrial Classification system or NAICS (pronounced "nakes").

The NAICS code for oncology small molecule drug discovery is 32511011. It is for this definition that aggregate latent demand estimates are derived. Oncology small molecule drug discovery is specifically defined as follows:

32511011 Aromatics (benzene, toluene, xylene, etc.), made in petrochemical plants

3251101111 Aromatics (benzene, toluene, xylene, etc.), for use as a chemical raw material, made in petrochemical plants

3251101121 Aromatics (benzene, toluene, xylene, etc.), for other uses, made in petrochemical plants